knowledge -WSS

knowledge

author：focus 2025-10-01 17:05:35 - browse：127

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： AI for drug discovery: Experts on separating hype from reality

WSS

Prior authorization will have to move faster under new Biden rule

Dewpoint Therapeutics lays off staff after losing partnerships

Test for long Covid? Researchers find new clue in blood samples

FDA clears AI tool for detecting skin cancer

Francis Collins on trust in science and how Covid communications failed

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

knowledge

focus

ChatGPT in medicine: STAT answers readers' burning questions

My yearlong odyssey to get my son’s ADHD medication covered

Anesthesiologist group: stop taking Ozempic before surgery

NIH director takes cautious approach to Biden drug pricing priority

Anesthesiologist group: stop taking Ozempic before surgery

New brain studies show LSD's effects on the brain in full color

Moonlake's readout produced a cash windfall. Risks remain

EU regulator recommends expanding Mounjaro approval to obesity

Anesthesiologist group: stop taking Ozempic before surgery

Elizabeth Holmes banned from government health programs

hotspot

How a small hospital in rural Puerto Rico survived Hurricane Maria

Dewpoint Therapeutics lays off staff after losing partnerships

Empower primary care with adequate payments and technology

Why doctors need education on FDA device approval process

Medicare Advantage today, explained in one chart

Class action alleges UnitedHealth concealed DOJ probe

focus

explore

leisure time

knowledge